These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30452928)

  • 21. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).
    Arsenault BJ; Boekholdt SM; Mora S; DeMicco DA; Bao W; Tardif JC; Amarenco P; Pedersen T; Barter P; Waters DD
    Am J Cardiol; 2014 Apr; 113(8):1378-82. PubMed ID: 24582532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.
    Akinkuolie AO; Glynn RJ; Padmanabhan L; Ridker PM; Mora S
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27413042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of future cardiovascular disease with an equation to estimate apolipoprotein B in patients with high cardiovascular risk: an analysis from the TNT and IDEAL study.
    Hwang YC; Ahn HY; Han KH; Park SW; Park CY
    Lipids Health Dis; 2017 Aug; 16(1):158. PubMed ID: 28830468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial.
    Kulik A; Abreu AM; Boronat V; Ruel M
    J Thorac Cardiovasc Surg; 2019 Jan; 157(1):151-161.e1. PubMed ID: 30122341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease.
    Li Q; Zhang Y; Ding D; Yang Y; Chen Q; Su D; Chen X; Yang W; Qiu J; Ling W
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4886-4894. PubMed ID: 27662438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
    LaRosa JC; Deedwania PC; Shepherd J; Wenger NK; Greten H; DeMicco DA; Breazna A;
    Am J Cardiol; 2010 Feb; 105(3):283-7. PubMed ID: 20102935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.
    Willke RJ; Zhou S; Vogel RA
    Curr Med Res Opin; 2008 Oct; 24(10):2873-82. PubMed ID: 18761783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
    Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease.
    Bittner V; Wenger NK; Waters DD; DeMicco DA; Messig M; LaRosa JC
    Am Heart J; 2012 Sep; 164(3):387-93. PubMed ID: 22980306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis.
    Ong KL; McClelland RL; Allison MA; Kokkinos J; Wu BJ; Barter PJ; Rye KA
    Atherosclerosis; 2019 Feb; 281():200-206. PubMed ID: 30446181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
    Bybee KA; Lee JH; O'Keefe JH
    Curr Med Res Opin; 2008 Apr; 24(4):1217-29. PubMed ID: 18358084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.
    Deedwania PC; Pedersen TR; DeMicco DA; Breazna A; Betteridge DJ; Hitman GA; Durrington P; Neil A;
    Int J Cardiol; 2016 Nov; 222():548-556. PubMed ID: 27513651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic effects of fibroblast growth factor‑21 against atherosclerosis via the NF‑κB pathway.
    Zhang Y; Liu Z; Zhou M; Liu C
    Mol Med Rep; 2018 Jan; 17(1):1453-1460. PubMed ID: 29257234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease.
    Kohara M; Masuda T; Shiizaki K; Akimoto T; Watanabe Y; Honma S; Sekiguchi C; Miyazawa Y; Kusano E; Kanda Y; Asano Y; Kuro-O M; Nagata D
    PLoS One; 2017; 12(6):e0178971. PubMed ID: 28582462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
    Shepherd J; Kastelein JP; Bittner VA; Carmena R; Deedwania PC; Breazna A; Dobson S; Wilson DJ; Zuckerman AL; Wenger NK;
    Mayo Clin Proc; 2008 Aug; 83(8):870-9. PubMed ID: 18674471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.